Allama Iqbal Memorial Teaching Hospital, Sialkot, Pakistan.
Birmingham Heartlands Hospital, United Kingdom.
J Ayub Med Coll Abbottabad. 2022 Apr-Jun;34(2):317-320. doi: 10.55519/JAMC-02-9365.
Iron deficiency is the most common nutritional deficiency worldwide. Common causes of IDA in children are excessive consumption of cow's milk and prolonged breast feeding with delayed and poor weaning. Oral iron is the first line of treatment in children with IDA but occasionally there is inadequate response due to poor compliance. The objective of this study is to assess the effectiveness and safety of intravenous iron in children with IDA, poorly compliant to oral iron therapy.
This study consisted of 90 children from 12-60 months with IDA who were not responding adequately to oral iron therapy. Total iron requirement was calculated and given intravenously (IV) in two divided doses over two consecutive days. Participants were followed up at 2 and 4 weeks to assess the rise in haemoglobin level. Any adverse event was also noted. SPSS version 25 was used for statistical analysis.
Of the 90 enrolled children the mean age was 23.1±10.7 months, 47 (52.2%) were males and 43(47.8%) were females. The mean ferritin level before IV iron therapy was 3.75±2.53 ng/ml and mean haemoglobin was 5.9±1.3 g/dL. After IV iron therapy the haemoglobin level was raised to 8.38±1.09 g/dl and 9.74±0.88 g/dl at 2 and 4 weeks respectively which was statistically significant (p<0.05). The adverse events were fever in 3 (3.3%) and urticaria in 2 (2.2%) patients.
Intravenous iron therapy is effective and safe to raise the haemoglobin levels in children with IDA who are poorly compliant to oral iron therapy.
铁缺乏是全世界最常见的营养缺乏症。儿童缺铁性贫血的常见病因是过量饮用牛奶和母乳喂养时间延长、添加辅食过晚且不合理。口服铁剂是儿童缺铁性贫血的一线治疗方法，但由于依从性差，偶尔会出现治疗反应不佳的情况。本研究旨在评估静脉铁剂治疗对口服铁剂治疗依从性差的缺铁性贫血儿童的有效性和安全性。
本研究纳入了 90 名 12-60 个月龄、口服铁剂治疗反应不佳的缺铁性贫血儿童。计算总铁需求量，并分两次在连续两天内静脉给予（IV）。在第 2 周和第 4 周时随访，以评估血红蛋白水平的升高情况。同时记录任何不良反应。采用 SPSS 25 版进行统计学分析。
在 90 名入组儿童中，平均年龄为 23.1±10.7 个月，其中 47 名（52.2%）为男性，43 名（47.8%）为女性。静脉铁剂治疗前，铁蛋白水平的均值为 3.75±2.53ng/ml，血红蛋白水平的均值为 5.9±1.3g/dL。静脉铁剂治疗后，血红蛋白水平分别升高至 8.38±1.09g/dl 和 9.74±0.88g/dl，在第 2 周和第 4 周时差异均有统计学意义（p<0.05）。不良反应包括发热 3 例（3.3%）和荨麻疹 2 例（2.2%）。
静脉铁剂治疗对口服铁剂治疗依从性差的缺铁性贫血儿童有效且安全，可提高血红蛋白水平。
